This paper is in the following e-collection/theme issue:

Reviews on Diabetes Technologies and Innovations (26) Diabetes (280) Respiratory Medicine (167) Prevention and Health Promotion (1449)

Published on in Vol 11 (2026)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/82215, first published .
Community-Acquired Pneumonia in Patients With Diabetes: Narrative Review

Community-Acquired Pneumonia in Patients With Diabetes: Narrative Review

Community-Acquired Pneumonia in Patients With Diabetes: Narrative Review

Authors of this article:

Yun Xie1 Author Orcid Image ;   Ao Zhang2 Author Orcid Image ;   Ying Wang3 Author Orcid Image ;   Ruilan Wang1 Author Orcid Image
Article Authors Cited by Tweetations Metrics

    1Department of Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    2Department of Critical Care Medicine, Shanghai General Hospital of Nanjing Medical University, Shanghai, China

    3Shanghai Institute of Immunology, Department of Immunology and Microbiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiaotong University School of Medicine, Shanghai, China

    Corresponding Author:

    Ruilan Wang, MD, PhD


    Background: Patients with diabetes carry a 1.5- to 2-fold higher risk of community-acquired pneumonia (CAP) and experience more severe outcomes, yet the mechanisms that integrate metabolic dysregulation, pathogen shifts, and novel cell death pathways remain fragmented.

    Objective: This study aimed to synthesize current evidence on epidemiology, pathophysiology, causative pathogens, clinical outcomes, and management of CAP in adults with diabetes and to identify research gaps for future trials.

    Methods: A narrative review (1999 to August 2025) of PubMed, EMBASE, the Cochrane Library, and Web of Science was conducted. GRADE (Grading of Recommendations Assessment, Development, and Evaluation) was used to rate evidence from 81 selected English-language studies (randomized controlled trials, cohorts, and meta-analyses).

    Results: Diabetes increases CAP incidence (relative risk 1.73, 95% CI 1.46‐2.04), hospitalization (+30%‐50%), and 30-day mortality (odds ratio 1.67, 95 % CI 1.45-1.92). Key drivers include hyperglycemia-induced immune paralysis, pulmonary microangiopathy, ferroptosis, glycation and methylation changes, and gut-lung dysbiosis that collectively favor multidrug-resistant Gram-negative bacilli (Klebsiella and Pseudomonas) and severe viral and fungal coinfections. Host-targeted therapy with moderate glycemic control (5‐10 mmol/L), continued metformin, and pathogen-directed antibiotics improves survival, whereas single-dose PCV20 and annual influenza vaccination prevents approximately 45% of CAP admissions. Emerging strategies (nanozymes, ferroptosis inhibitors, probiotics, and proteolysis-targeting chimeras) are still preclinical.

    Conclusions: CAP in patients with diabetes is a distinct, more severe entity mediated by metabolic-immune crosstalk. Multicenter randomized controlled trials integrating tight glucose monitoring, novel host-directed agents, and microbiome modulation are warranted to translate mechanistic insights into better outcomes.

    JMIR Diabetes 2026;11:e82215

    doi:10.2196/82215

    Keywords

    diabetes mellitus; community-acquired pneumonia; pathophysiology; pathogens; complications; treatment; prevention; microbiome 


    Diabetes mellitus (DM), affecting more than 537 million individuals worldwide [1], significantly increases susceptibility to infections, including community-acquired pneumonia (CAP) [2]. CAP is a leading cause of morbidity and mortality worldwide, with patients with diabetes experiencing higher rates of hospitalization (30%‐50% higher), complications, and mortality (odds ratio [OR] 1.6) compared with those without diabetes [3,4]. The interplay of hyperglycemia, immune dysfunction, and comorbidities creates a “triple threat,” predisposing patients with diabetes to severe CAP and complicating treatment [5]. This review provides a comprehensive, critical analysis of CAP in patients with diabetes, integrating epidemiological data, pathophysiological mechanisms, pathogen profiles, clinical outcomes, and management strategies. It emphasizes novel research areas (eg, ferroptosis, microbiome influences, and epigenetic modifications) and evaluates the strength and limitations of current evidence, distinguishing between clinical, in vitro, and animal studies to clarify translational relevance (Figure 1).

    Patients with diabetes have a 1.5- to 2.5-fold greater risk of pneumonia due to hyperglycemia and immune dysfunction [6]. They experience more severe infections and complications, leading to higher mortality rates. Targeted therapies and vaccines are crucial for managing pneumonia in patients with diabetes.

    ‎
    Figure 1. Multiple risks and influencing factors for community-acquired pneumonia (CAP) in patients with diabetes. ICU: intensive care unit.

    This is a narrative review synthesizing evidence on CAP in patients with diabetes, focusing on epidemiology, pathophysiology, pathogens, outcomes, and management. We conducted a systematic literature search in PubMed, EMBASE, the Cochrane Library, and Web of Science from January 1999 to August 2025, using the following terms: (“diabetes mellitus” OR “type 2 diabetes”) AND (“community-acquired pneumonia” OR “CAP”) AND (epidemiology OR pathophysiology OR pathogens OR treatment OR prevention) (Multimedia Appendix 1). Inclusion criteria were English-language studies (randomized controlled trials [RCTs], cohorts, and meta-analyses) on adults aged 18 years or older; exclusion criteria were pediatric studies, hospital-acquired pneumonia, and nonhuman studies without translational relevance. We screened 1248 abstracts, reviewing 156 full texts; of these, 81% (156/1248) were included. Evidence was graded using GRADE (Grading of Recommendations Assessment, Development, and Evaluation): high (RCTs or meta-analyses), moderate (cohorts), low (case series or animal studies), and very low (in vitro studies or hypothesis). Quantitative claims include 95% CIs and designs where available.


    Epidemiology

    The annual incidence of CAP ranges from 1.5 to 14 cases per 1000 adults, with patients with diabetes facing a 1.5- to 2-fold higher risk (10‐20 cases per 1000) [7]. A 2024 meta-analysis of observational studies (pooled sample size >1 million) reported a relative risk of 1.73 (95% CI 1.46-2.04) for pneumonia in patients with diabetes, primarily those with type 2 diabetes, although the findings were limited by heterogeneity in metrics of glycemic control and the lack of RCTs [6]. Rates of hospitalization are 30% to 50% higher, and 30-day mortality odds are 1.6-fold greater in patients with diabetes and CAP, with observational studies showing consistent trends but with potential confounding by comorbidities [4,8]. Poor glycemic control (glycosylated hemoglobin A1c [HbA1c] ≥7%) doubles the risk of severe outcomes such as sepsis (odds ratio [OR] 2.0, 95% CI 1.4‐2.8), with in-hospital mortality ranging from 10% to 20% in clinical cohorts [9]. Low- and middle-income countries (LMICs) face a higher CAP burden due to rising diabetes prevalence and limited health care access, although data are limited by underreporting [10]. People with DM were at higher risk for invasive pneumococcal disease (unadjusted OR 2.42, 95% CI 2.00-2.92) and case fatality rate (unadjusted OR 1.61, 95% CI 1.25-2.07), after adjusting for age, obesity, and smoking in propensity-matched cohorts (high, meta-analyses) [4,6]. Diabetes significantly increases the probability of secondary pneumonia in patients with COVID-19 (moderate, time series [11]). Although observational studies consistently report a 1.5- to 2.0-fold risk, recent RCTs using continuous glucose monitoring (CGM) address confounding. In a 2025 RCT of 124 frail, critically ill patients with COVID-19 (30% with diabetes), CGM-guided glycemic control reduced 28-day intensive care unit (ICU) mortality by approximately 80% (hazard ratio 0.18, 95% CI 0.04‐0.79), with benefit independent of baseline HbA1c levels [12]. These findings underscore the need for more RCTs to confirm observational data and address biases such as selection and ascertainment (Figure 2, Table 1).

    ‎
    Figure 2. Flow diagram.
    Table 1. Epidemiological features of community-acquired pneumonia (CAP) in patients with and without diabetes.
    OutcomePatients with diabetesPatients without diabetesEstimate (95% CI)Study design and sampleEvidence gradeaKey references
    Annual incidence8‐12/1000 adults3‐6/1000 adultsIRRb 1.66 (1.65‐1.67)National discharge cohort ≈900,000HighKornum et al [8] and López-de-Andrés et al [4]
    RRc (any CAP)—d1 (ref)eRR 1.26 (1.21‐1.31)Population-based case-controlHighKornum et al [8]
    CAP-related hospitalization+26%‐66% versus non-DMfBaselineIRR 1.66 (1.65‐1.67)National cohort ≈900,000HighLópez-de-Andrés et al [4]
    30-d mortality after CAP12%‐14%13%‐14%ORg 0.92 (0.91‐0.94) lowerNational cohort ≈900,000HighLópez-de-Andrés et al [4]
    Invasive pneumococcal disease—1 (ref)OR 2.42 (2.00‐2.92) unadjustedMeta-analysis 36 studies >9 millionHighSilverii et al [6]
    Case fatality rate (IPDh)—1 (ref)OR 1.61 (1.25‐2.07) unadjustedMeta-analysis 19 studiesHighSilverii et al [6]
    Severe course or sepsis (HbA1ci ≥7%)—1 (ref)HR 1.52 (1.37‐1.68)National diabetes registry ≈500,000HighBalintescu 2021 [9]

    aEvidence grade: high=national registry or large meta-analysis; moderate=single prospective cohort; low=case series.

    bIRR: incidence rate ratio.

    cRR: relative risk.

    dNot applicable.

    eref: reference.

    fDM: diabetes mellitus.

    gOR: odds ratio.

    hIPD: invasive pneumococcal disease.

    iHbA1c: glycosylated hemoglobin A1c.

    Pathophysiological Mechanisms

    Immune Dysregulation

    Hyperglycemia impairs innate and adaptive immunity, reducing neutrophil chemotaxis, phagocytosis, and bactericidal activity, which are critical for clearing pathogens such as Streptococcus pneumoniae [13]. The nucleotide-binding oligomerization domain–like receptor thermal protein domain–associated protein 3 (NLRP3) inflammasome’s hyperactivation drives excessive interleukin (IL)-1β and IL-6 production, exacerbating lung damage, as demonstrated in murine models of diabetes and pneumonia [14]. However, these models may not fully replicate human immune responses due to species-specific differences in inflammasome regulation. Decreased interferon-gamma production and altered T-cell responses, including reduced regulatory T cells, further compromise immunity, with in vitro studies showing a reduction in interferon-gamma in T cells from patients with diabetes [15]. A 2021 systematic review and meta-analysis (n=449,247) indicated that type 2 DM is associated with an approximately 2-fold increased risk of multidrug-resistant (MDR) bacterial infections, with underlying immune suppression in patients with diabetes proposed as a key contributing mechanism, although heterogeneity across included studies (I² up to 58.1%) should be noted [16].

    Pulmonary Microangiopathy

    Chronic hyperglycemia causes microvascular damage, impairing endothelial function and gas exchange, thereby facilitating pathogen colonization [17,18[19]]A retrospective cohort study demonstrated an increased risk of mortality in patients with severe CAP and type 2 diabetes complicated by microvascular disease, such as nephropathy and retinopathy, who often presented with computed tomography evidence of multilobar infiltrates [20]. These findings are supported by animal models showing increased vascular permeability in the lungs of animals with diabetes, although human studies are needed to validate these mechanisms.

    Hyperglycemia and Glycemic Variability

    Admission hyperglycemia (>11.1 mmol/L) is a strong predictor of poor CAP outcomes, with a 2024 meta-analysis (n=12 studies, >10,000 patients) reporting a pooled OR of 2.47 (95% CI 1.73‐4.12) for short-term mortality [21]. Acute hyperglycemia exacerbates oxidative stress, while chronic hyperglycemia sustains endothelial dysfunction, as shown in clinical cohorts [22,23]. A 2015 retrospective cohort study (n=203) demonstrated that an elevated glycemic gap—a marker of acute glycemic variability—was associated with a 3‐ to 4-fold increased risk of adverse outcomes, including acute respiratory failure requiring mechanical ventilation in patients with diabetes and CAP, underscoring the importance of dynamic glucose monitoring [24]. Long-term CGM or serial HbA1c trajectories are needed to determine whether sustained versus transient hyperglycemia drives pneumonia risk. Distinguishing acute versus chronic hyperglycemia effects remains a research hotspot, as most studies focus on admission glucose levels without longitudinal data.

    Ferroptosis

    Iron overload and hepcidin overexpression in patients with diabetes promote ferroptosis, an iron-dependent programmed cell death mechanism, exacerbating pulmonary inflammation and injury in murine models of diabetes (low, animal [25]). An in vitro study demonstrated that ferroptosis inhibitors (eg, ferrostatin-1) reduced lung epithelial cell death in high-glucose conditions, suggesting therapeutic potential [25]. In murine models of diabetes, ferroptosis was linked to acute respiratory distress syndrome (ARDS)–like pathology in CAP, although clinical trials are lacking to confirm these findings in humans. Emerging humanized models bridge the gap. In diabetes-derived organoids, high-glucose conditions upregulate NLRP3 and impair phagocytosis, recapitulating ferroptosis [26], human organoids show glutathione peroxidase 4 downregulation (very low, in vitro [26]). Targeting ferroptosis pathways could mitigate severe CAP outcomes, but challenges include identifying safe, specific inhibitors for more clinical use.

    Glycation and Methylation

    Nonenzymatic glycation alters protein structures (eg, angiotensin-converting enzyme 2), impairing function and worsening pneumonia severity, as shown in in vitro studies of lung tissue from patients with diabetes [27]. Methylation dysregulates immune gene expression, increasing CAP susceptibility, with a 2020 study identifying hypermethylation of IL-6 promoters in patients with diabetes and CAP [27]. Targeting glycation with inhibitors such as aminoguanidine or methylation with demethylating agents (eg, 5-azacytidine) shows promise in preclinical studies but requires RCTs to establish efficacy and safety.

    RNA-Level Mechanisms

    Gu et al [28] found that zinc finger E-box binding homeobox 1 antisense 1 (ZEB1-AS1) was downregulated in lung tissue from patients with diabetes and in high-glucose–treated BEAS-2B cells; this downregulation increased p53 and apoptosis in vitro. Hyperglycemia exacerbates this downregulation, increasing lung injury in murine models of diabetes. These findings suggest ZEB1-AS1 as a potential therapeutic target, but human studies are needed to validate its role and to develop RNA-based therapies, such as small interfering RNA or Clustered Regularly Interspaced Short Palindromic Repeats–based approaches.

    Microbiome Alterations

    Diabetes alters the lung and gut microbiome, promoting Gram-negative pathogens such as Klebsiella pneumoniae [29].[30] Zhou et al [31] conducted a multiomics longitudinal study of 86 participants with prediabetes or T2D risk, integrating 16S ribosomal RNA sequencing, metabolomics, and host cytokine profiles and found that insulin-resistant individuals exhibited Akkermansia depletion alongside elevated phenylalanine-associated metabolites, which correlated with increased respiratory infection events, supporting a gut-lung axis link. Fecal transplantation from diabetes-affected donors to mice increased K pneumoniae colonization, which was reversed by Akkermansia depletion. Preclinical studies in mice with diabetes suggest that probiotics (eg, Lactobacillus) could restore microbial balance and reduce CAP severity. On the basis of the pooled analysis of 9 randomized trials in a study by Manzanares et al [32], probiotics reduced the risk of new-onset ventilator-associated pneumonia by 26% (RR 0.74, 95% CI 0.61‐0.90), although causality remains in the absence of CAP-specific RCTs. On the basis of the PROSPECT pilot trial (Cook et al [33]), 150 critically ill ventilated patients received L rhamnosus GG, achieving 97% protocol adherence and an observed ventilator-associated pneumonia rate of 19%, supporting feasibility for a larger RCT on probiotic prevention of ICU-acquired pneumonia. Additional clinical trials are needed to confirm efficacy (Figure 3, Table 2).

    ‎
    Figure 3. Pathophysiological mechanisms of community-acquired pneumonia in patients with diabetes. Hyperglycemia enhances macrophage inflammatory responses, releasing interleukin (IL)-6 and IL-1β, while impairing neutrophil chemotaxis and phagocytosis. Activation of nuclear factor kappa-B (NF-κB) and tumor necrosis factor receptor–associated factor (TRAF) pathways damages vascular endothelial cells, and ACE2 degradation exacerbates renin-angiotensin-aldosterone system (RAAS) activation, increasing cardiovascular complications. Bacterial superantigens (eg, toxic shock syndrome toxin-1 [TSST-1] from S. aureus) induce insulin resistance, creating a vicious cycle. ACE2: angiotensin-converting enzyme 2; AP: activator protein; GLUT-4: glucose transporter type 4; ICAM: intercellular adhesion molecule; IKKB: inhibitor of nuclear factor kappa B kinase subunit beta; NET: neutrophil extracellular trap.
    Table 2. Pathophysiological mechanisms of community-acquired pneumonia (CAP) in patients with diabetes.
    MechanismDescriptionImpact on CAPReferences and evidence
    Immune dysregulationPersistent hyperglycemia impairs neutrophil chemotaxis, phagocytosis, and oxidative burst; NLRP3b inflammasome hyperactivation increases ILc-1β/IL-6, while IFNd-γ and regulatory T-cell responses are reduced.Delayed clearance of S. pneumoniae and MDRe pathogens; ~2-fold higher risk of MDR infection; exaggerated lung inflammation.Meta-analysis, n=449,247, I²=58%, high quality [13-16]
    Pulmonary microangiopathyChronic hyperglycemia thickens the alveolar-capillary basement membrane, increases microvascular permeability, and impairs gas exchange.Promotes multilobar infiltrates; higher mortality when retinopathy and nephropathy coexist.Retrospective cohort, moderate quality [17,18,20]
    Hyperglycemia and glycemic variabilityAdmission glucose >11.1 mmol/L or wide glycemic excursions enhance oxidative stress and sustained endothelial NF-κBf activation.Short-term mortality ORg 2.47 (95% CI 1.73‐4.12); 3‐ to 4-fold more likely to require mechanical ventilation.Meta-analysis 12 studies, n >10,000, high quality [21-24]
    FerroptosisIron overload (↑ hepcidin, free Fe²+) triggers iron-dependent lipid peroxidation and death of alveolar epithelial cells.Amplifies lung injury; ARDS-likeh histology in diabetic mice; ferrostatin-1 protective in vitro or rodent models.Animal and organoid studies, low quality [25,26]
    Glycation and methylationNonenzymatic glycation modifies ACE2i, surfactant proteins; promoter hypermethylation maintains high IL-6 transcription.Compromised protein function, sustained inflammatory gene expression, greater CAP severity.Clinical+in vitro, low-moderate quality
    RNA-level mechanismsHyperglycemia ↓ lncRNA ZEB1-AS1j → p53 ↑ → alveolar epithelial apoptosis.Larger radiological lesions; siRNAk or CRISPRl modulation under investigation.Human tissue+BEAS-2B cells, very low quality
    Microbiome alterationsGut-lung axis dysbiosis: Akkermansia depletion, expansion of Klebsiella and other G⁻ bacilli, accompanied by proinflammatory phenylalanine metabolites.2‐ to 3-fold rise in G⁻ or MDR CAP and recurrence; probiotics lower VAPm risk by 26% (RRn 0.74, 9 RCTso), but CAP-specific RCTs pending.Longitudinal multiomics+probiotic meta-analysis, moderate quality [29,31,32,34]

    bNLRP3: NOD-like receptor thermal protein domain–associated protein 3.

    cIL: interleukin.

    dIFN: interferon.

    eMDR: multidrug-resistant.

    fNF-κB: nuclear factor kappa-B.

    gOR: odds ratio.

    hARDS: acute respiratory distress syndrome.

    iACE2: angiotensin-converting enzyme 2.

    j ZEB1-AS1: zinc finger E-box binding homeobox 1 antisense 1.

    ksiRNA: small interfering RNA.

    lCRISPR: Clustered Regularly Interspaced Short Palindromic Repeats.

    mVAP: ventilator-associated pneumonia.

    nRR: relative risk.

    oRCT: randomized controlled trial.

    Primary Pathogens

    Bacterial Pathogens

    Streptococcus pneumoniae accounts for approximately 8% of CAP cases in patients with diabetes, with higher bacteremic rates [4]. In the European multicenter CAPNETZ cohort (2002‐2022), Streptococcus pneumoniae remained the predominant pathogen, identified in 36% of patients with diabetes and CAP and 39% of patients with CAP and without diabetes with an identified organism (2954/13,611), adults with diabetes and CAP exhibited a significantly higher isolation rate of Enterobacteriaceae (13% vs 8%; P<.005) and modest differences in Haemophilus influenzae (8%), atypical bacteria (9%), and viruses (22%) compared with individuals with diabetes, while Staphylococcus aureus and nonfermenting Gram-negative bacilli each accounted for approximately 3% to 4% in both groups [35]. Klebsiella pneumoniae (15%‐20%) and Pseudomonas aeruginosa are prevalent, often multidrug-resistant, complicating treatment [36]. Klebsiella pneumoniae caused 13% of microbiologically confirmed CAP in European adults with diabetes (CAPNETZ 2002‐2022) [35] and 78% of carbapenem-resistant isolates in a 2021 Indian cohort of patients with diabetes [37]; data from these settings indicate its importance in CAP among patients with diabetes, but population-based proportions in Asian LMICs remain to be established. A 2024 single-center prospective study from Mangalore, southern India, found that among hospitalized patients, the proportion of individuals with diabetes infected with carbapenem-resistant Klebsiella pneumoniae (CRKP) was approximately twice that of individuals without diabetes (78% vs 39%) [37]. Legionella pneumophila causes severe disease, especially in immunocompromised patients or patients with diabetes, and carries a higher mortality risk when diagnosis or appropriate antibiotic therapy is delayed [38]. In adult CAP across the Asia-Pacific region, Streptococcus pneumoniae remains the most frequently detected bacterium in patients with diabetes (≈10%‐24%), yet K pneumoniae (≈10%‐20%, up to 40% in Malaysia and Thailand), Haemophilus influenzae (≈5%‐24%), and Pseudomonas aeruginosa or Burkholderia pseudomallei (20%‐30% in ICU settings) are recovered far more often than reported in Western series. Atypical pathogens and mixed infections each account for roughly one-quarter of cases [39].

    Viral Pathogens

    Influenza and SARS-CoV-2 are significant, with patients with diabetes showing higher rates of severe pneumonia and ARDS [40]. Elevated ACE2 expression in patients with diabetes facilitates SARS-CoV-2 entry, worsening outcomes [41]. A 2023 study highlighted a 4.64-fold increased risk of COVID-19–related ARDS in patients with diabetes [42].

    Fungal Pathogens

    Opportunistic fungi such as Aspergillus and Candida are more common in patients with diabetes due to immune suppression, with pulmonary aspergillosis carrying a 50% to 70% mortality rate [43]. Pneumocystis jirovecii and mucormycosis are notable in patients with poorly controlled diabetes [44]. A 2020 study reported a higher incidence of invasive fungal infections in patients with diabetes, with the prevalence of invasive fungal disease among hospitalized patients with type 2 diabetes to be 0.4%, approximately double that of the 0.2% observed in inpatients without diabetes [44]. Fungal CAP remains uncommon (<5%), but post–COVID reports are rising; in patients with diabetes—a classic driver of mucormycosis—preguideline Indian series already showed attack rates of approximately 0.1 to 0.3 per 1000 and mortality of approximately 50% (low-certainty data [45]), a signal now echoed in Asian cohorts of patients with diabetes.

    Atypical Pathogens

    Mycoplasma salivarium and Legionella cause severe infections in patients with diabetes, often presenting atypically, necessitating early diagnosis [46]. A 2023 case report documented severe M. salivarium empyema in a patient with diabetes [46].

    Clinical Outcomes

    Patients with diabetes and CAP required invasive mechanical ventilation in 1.6 % of admissions (vs 2.1% in patients without diabetes) and had slightly higher overall risk-adjusted odds of in-hospital mortality, although the database did not capture ICU admission rates or radiographic extent of disease [4]. Hyperglycemia amplifies systemic inflammation and complement dysfunction, and population studies cited in 2024 show that diabetes carries an overall 1.5 to 4-fold increase in infection-related hospitalization, with the risk gradient most pronounced for sepsis, pneumonia, and renal infection [47]. In a 2023 Iranian cross-sectional study of 172 hospitalized patients with CAP, those with diabetes incurred a median CURB-65 score of 3 versus 2 in those without diabetes, required ICU admission more than 3 times as often (22% vs 7%), and stayed a mean of 8.5 days versus 7.9 days, underscoring diabetes as an independent predictor of more severe pneumonia course [48]. Complications include higher rates of pleural effusion and respiratory failure, with MDR pathogens increasing complication rates[49]. Among 600 patients with K pneumoniae infection, patients with diabetes exhibited 78% CRKP and 71% MDR rates versus 39% and 11% in those without diabetes and carried a 27% infection-related mortality (vs 2%), illustrating how MDR pathogens amplify severe outcomes in patients with diabetes [37] (Table 3).

    Table 3. Primary pathogens causing community-acquired pneumonia (CAP) in adults with diabetes.
    PathogenProportion in DMb-CAPLocation/technique/settingMortality (95% CI)Strength of evidenceKey references
    Bacteria
    Streptococcus pneumoniae8%‐36%Global; sputum/BALc culture+ PCRd; community and hospital10%‐15% (8%‐18%)High (multicenter cohort n≈13,000)[4, 35]
    Klebsiella pneumoniae (MDRe/CRKPf)10%‐20% (up to 40% ICUg, Asia)Asia-Pacific, India; culture; hospital and ICU20%‐25% (15%‐30%)Moderate (prospective center n≈600)[36,37,39]
    Haemophilus influenzae5%‐24%Asia-Pacific; culture/PCR; community8%‐12%Moderate (cohort n≈3000)[35, 39]
    Pseudomonas aeruginosa3%‐4% (Western) → 20%‐30% (ICU, Asia)hCulture; ICU and hospital25%‐35%Moderate (ICU cohorts)[35, 39]
    Staphylococcus aureus (including MRSA)i3%‐4%Culture; community and hospital30%‐40%Low (case series)[35, 50]
    Legionella pneumophila1%‐3%Urine Ag/PCR; community and travel associated10%‐30%Moderate (surveillance)[38]
    Viruses
    SARS-CoV-210%‐15% (COVID era)PCR; community and hospitalARDSj ORk 4.6 (3.2‐6.7)High (meta-analysis n>100 000)[40,42]
    Influenza A/B5%‐10%PCR; community and hospital10%‐20%High (seasonal surveillance)[20]
    Fungi
    Aspergillus spp. (including IPAl)<5% (0.4% invasive)BAL GMm/culture/biopsy; ICU and immunosuppressed50%‐70% (40%‐80%)Low (case series)[43,44]
    Candida spp. (pulmonary)<2%BAL culture/biopsy; ICU20%‐40%Very low (case reports)[43]
    Mucorales (mucormycosis)0.1‐0.3% (diabetes cohort)Biopsy/culture; ICU (post-COVID)≈50%Low (national surveys)[44,45]
    Atypical bacteria
    Mycoplasma pneumoniae5%‐10%PCR/serology; community1%‐3%Moderate (surveillance)[39,46]
    Legionella pneumophilan1%‐3%See above—o——

    bDM: diabetes mellitus.

    cBAL: bronchoalveolar lavage.

    dPCR: polymerase chain reaction.

    eMDR: multidrug-resistant.

    fCRKP: carbapenem-resistant Klebsiella pneumoniae.

    gICU: intensive care unit.

    hProportions are median ranges from Western (CAPNETZ) and Asia-Pacific cohorts unless specified.

    iMRSA: methicillin-resistant Staphylococcus aureus.

    jARDS: acute respiratory distress syndrome.

    kOR: odds ratio.

    lIPA: invasive pulmonary aspergillosis.

    mGM: galactomannan.

    nListed once under “bacteria”; totals may overlap in mixed infections.

    oNot applicable.

    Treatment Strategies

    Pathogen-Targeted Therapy
    Bacterial Pneumonia

    Given the high prevalence of MDR pathogens in patients with diabetes and CAP, such as CRKP and methicillin-resistant Staphylococcus aureus, targeted therapy is critical. For severe CAP, antibiotics such as vancomycin or linezolid (for methicillin-resistant Staphylococcus aureus) and polymyxins or tigecycline (for CRKP) are recommended based on susceptibility testing [36]. A 2024 study reported a higher incidence of CRKP in adults with diabetes and CAP, emphasizing the need for rapid diagnostics and tailored therapy [37]. Nanozymes, such as BiPt@HMVs, show promise in combating multidrug-resistant bacteria, with a 2023 study demonstrating approximately 3-log bacterial clearance and significant alleviation of lung inflammation in a mouse model of MDR pneumonia [51]. Empiric therapy with β-lactam (eg, ceftriaxone) plus a macrolide (eg, azithromycin) remains appropriate for nonsevere cases, but culture-guided de-escalation is essential to minimize resistance [52]. The 2023 ERS/ESICM/ESCMID/ALAT guidelines identify diabetes as a risk factor for drug-resistant pathogens in severe CAP and suggest integrating local epidemiology and prior colonization history to guide empirical antibiotic choices, including coverage for resistant Gram-negative bacteria such as Enterobacterales [53]. Bacterial: Empiric β-lactam (ceftriaxone)+macrolide (azithromycin) for nonsevere CAP (high, guidelines); add vancomycin for MDR risk in DM (eg, prior hospitalization; moderate [52]).

    Viral Pneumonia

    Early identification of viral pathogens, such as influenza or SARS-CoV-2, is crucial for effective management. Rapid molecular diagnostics (eg, polymerase chain reaction) enable the timely initiation of antivirals such as oseltamivir for influenza or remdesivir for COVID-19 [54]. A 2023 study reported a reduction in COVID-19 pneumonia severity with remdesivir in patients with diabetes [55]. Antiviral resistance, particularly to oseltamivir in influenza, is a growing concern; combination therapies (eg, oseltamivir with baloxavir) or novel agents such as programmed death-ligand 1 inhibitors may mitigate resistance risks [56]. A 2021 study highlighted the importance of early antiviral therapy within 48 hours of symptom onset to reduce complications in patients with diabetes [54]. As recommended by the CDC, prompt initiation of oseltamivir for influenza or remdesivir for COVID-19 is strongly advised in diabetic patients with viral pneumonia [54].

    Fungal Pneumonia

    Fluconazole for Candida and voriconazole for Aspergillus are standard medications, with DectiSomes enhancing targeted delivery [57]. DectiSomes, a novel liposomal delivery system targeting fungal glycans, significantly enhance antifungal drug efficacy. In murine models of pulmonary aspergillosis, DectiSomes achieved a 12- to 42-fold reduction in fungal burden compared to untargeted liposomal amphotericin B.

    Host-Targeted Therapy

    Glycemic Control

    Maintaining blood glucose within a flexible range of 5 to 10 mmol/L is recommended to reduce mortality (OR 0.62) while minimizing the risk of hypoglycemia, which is a concern with stricter targets (4‐8 mmol/L) in clinical practice [21]. Insulin protocols with frequent monitoring (eg, every 2‐4 h) help stabilize glycemic variability, particularly in critically ill patients [22]. A 2022 study confirmed that moderate glycemic control (5‐10 mmol/L) reduced ICU admission by 25% in patients with diabetes and CAP without significant hypoglycemic events [58]. Targets include 140 to 180 mg/dL (7.8‐10.0 mmol/L) in critically ill CAP (high, 2025 ADA [59]); distinctions include admission hyperglycemia with an OR of 2.47 for mortality (95% CI 1.9‐3.2; high, meta-analysis [21]); HbA1c ≥7% associated with a doubling of sepsis risk (low [9]); and glycemic variability (CV>36%) associated with a 2.5-fold increase in the need for ventilation (moderate RCT [60v])—severity-adjusted length of stay was reduced by 1.7 days with glycemic control (moderate RCT, n=200 [48]).

    Metformin

    Metformin continuation was linked to 14% lower 30-day mortality in patients with diabetes and CAP (HR 0.86, 95% CI 0.78‐0.95; moderate certainty, 2023 US Veterans cohort, n≈15,000 [61]). While these data are encouraging, confirmation in broader, nonveteran RCTs is still required.


    Adjunctive Therapies

    Low-dose corticosteroids (eg, methylprednisolone 0.5 mg/kg/d) reduce the need for ventilation but require careful glycemic monitoring to prevent hyperglycemia [62]. Metformin continuation is linked to lower mortality. A 2023 study found that metformin reduced 30-day mortality by 14% in patients with diabetes and CAP [61].

    Comorbidity Management

    Optimizing heart failure and renal function reduces adverse events. Renal-dose antibiotic adjustments are critical [4]. A 2021 study reported a reduction in complications with optimized comorbidity management [63].

    Management in LMICs

    In LMICs, where DM prevalence is rising fastest, an estimated 537 million adults had DM in 2021, of whom 80.6% lived in LMICs [1]; scarce resources magnify the CAP burden [10]. Diagnostics favor rapid antigen or polymerase chain reaction over culture (World Health Organization, low resource, moderate quality [64]); screening for DM should be performed with point-of-care fasting plasma glucose or HbA1c instead of laboratory oral glucose tolerance testing (World Health Organization, low resource, moderate quality [64]). Empirical therapy administers amoxicillin-clavulanate for nonsevere CAP (with adjustment for local resistance; Pan American Health Organization, high quality [64]) and deescalates using biomarkers such as C-reactive protein. For vaccination, roll out and expand PCV20 immunization campaigns (45% efficacy against pneumococcal pneumonia [65]); for glucose management, use sliding-scale insulin targeting 5 to 10 mmol/L [59]. Multidisciplinary teams reduce complications by 20% (2023 consensus, low quality [64]).

    Preventive Measures

    Pneumococcal (PPSV23) and influenza vaccinations reduce CAP hospitalization by 30% in patients with diabetes, although efficacy may be reduced due to immune dysregulation [66]. A 2023 study demonstrated a 45.6% (95% CI 21.8%‐62.5%) efficacy of PCV13 against vaccine-type pneumococcal CAP in adults aged 65 years or older [65]. Regular glycemic control and lifestyle interventions (eg, nutrition and exercise) bolster immunity [67]. According to the 2024 Advisory Committee on Immunization Practices 2024 recommendations [68], pneumococcal vaccination with a single dose of PCV20 and PCV21 is recommended for adults aged 50 years or older with DM (high, guidelines; efficacy 45%‐60% vs vaccine-type CAP [65]); and adults aged 50 years or older with diabetes should receive timely pneumococcal vaccine to reduce the increased risk of CAP and invasive pneumococcal disease (high, guidelines [66]). A single dose of PCV20 completes pneumococcal vaccination—with no additional PPSV23 required—while annual influenza immunization remains essential for adults aged 50 years or older with diabetes (high evidence [66]). After 2 CoronaVac doses, people with well-controlled type 2 diabetes produced only slightly lower SARS-CoV-2 antibody levels than healthy workers (58 vs 72 BAU/mL, P=.74), but those who also had dyslipidemia had a much weaker response (50 vs 342 BAU/mL, P<.001) [69].

    Future Research Directions

    Autophagy Regulation

    Autophagy-inducing compounds reduce SARS-CoV-2 propagation [70]. A 2021 study reported that autophagy inducers reduced SARS-CoV-2 viral load by up to 90%, depending on the compound and conditions [70]. However, no clinical data are available in patients with diabetes and CAP (very low, preclinical [51,70,71]).

    Proteolysis-Targeting Chimeras

    CYPA-ProTACs target host cofactors, enhancing antiviral effects [72]. A 2021 study showed that PROTAC derivatives of indomethacin exhibited up to a 5-fold improvement in antiviral potency against SARS-CoV-2 compared to the parent compound [72]. No clinical data are available in patients with diabetes and CAP (very low, preclinical [51,70,71]).

    Nanoparticle Delivery

    Phage-like nanocarriers improve antibiotic efficacy [73]. A 2024 study demonstrated that T7 phages armed with silver nanoparticles significantly reduced Escherichia coli biofilm biomass and bacterial viability, outperforming either phages or nanoparticles alone [73]. No clinical data are available in patients with diabetes and CAP (very low, preclinical [51,70,71]).

    Microbiome Impact

    Alterations in the gut and lung microbiome influence CAP susceptibility and severity in patients with diabetes [29]. A 2025 study suggested that microbiome modulation could reduce CAP recurrence [34]. Future research should explore probiotics and prebiotics as adjunctive therapies.

    Vaccination Strategies

    Evaluating the efficacy of adjuvanted or combination vaccines in patients with diabetes could enhance immunization outcomes [69]. A 2023 study reports that receiving CoronaVac is still beneficial for patients with diabetes, although their measured anti–receptor-binding titers were numerically (but not significantly) lower than those of health care workers [69].

    Novel Therapies

    Targeting ferroptosis, glycation, methylation, and lncRNA ZEB1-AS1 offers potential therapeutic avenues in patients with diabetes [25,27,28]. Integrating traditional Chinese medicine with conventional treatments shows promise [74]. A 2020 study reported that integrated Chinese medicine was associated with significantly higher rates of clinical symptom resolution (fever: 80.3% vs 53.1%, fatigue: 77.6% vs 53.8%, cough: 66.1% vs 42.9%, and sputum production: 85.3% vs 46.2%; P<.05 or P<.01) and a 13% relative reduction in hospitalization (10.98% vs 24.39%) compared with usual care alone [74].

    Limitations and Future Directions

    This review has several limitations. First, most epidemiological data are observational and prone to confounding; RCTs are needed to confirm causality. Second, mechanisms such as ferroptosis and NLRP3 activation rely on animal models, with limited human validation despite emerging organoid data [26]. Third, acute versus chronic hyperglycemia effects remain unclear, although CGM-guided RCTs are addressing this gap [60]. Fourth, microbiome dysbiosis lacks causal evidence; multiomics and probiotic RCTs are required [31,33]. Fifth, novel therapies (eg, ferroptosis inhibitors and aminoguanidine) show preclinical promise but have not been evaluated in RCTs involving adults with diabetes and CAP [75,76]; these novel agents remain very-low-certainty preclinical candidates [71] and demand RCTs. With approximately 80% of CAP caused by bacterial pathogens [35], therapeutic efforts must rebalance toward these nonviral pathogens. Future research should prioritize multicenter RCTs integrating CGM, probiotics, and host-targeted agents to translate mechanisms into clinical benefit.

    Conclusions

    Patients with diabetes face heightened CAP risks due to immune dysregulation, hyperglycemia, and microbial shifts, leading to severe disease, complications, and mortality. Early antibiotics targeting special pathogens, rapid antiviral therapy, and moderate glycemic control (5‐10 mmol/L) are critical. Multidisciplinary care and novel therapies targeting metabolic and immune pathways are essential to improve outcomes. Continued research into microbiome influences, epigenetic mechanisms, and innovative treatments will address emerging challenges in this vulnerable population.

    Funding

    This study was supported by the Clinical Research Innovation Plan of Shanghai General Hospital (CCTR-2025C09), National Key Clinical Specialist Construction Project (Z155080000004), National Key Research and Development Program of China (2024YFC3044400), the Key Supporting Discipline of Shanghai Healthcare System (2023ZDFC0102), the Science and Technology of Shanghai Committee (23Y31900100), and Noncommunicable Chronic Diseases-National Science and Technology Major Project (2023ZD0506502).

    Data Availability

    All data generated or analyzed during this study are included in this published article.

    Authors' Contributions

    YX and RW were involved in the conception and design. All authors were involved in the writing of the manuscript. All authors were involved in the final approval of the manuscript.

    YW is the co-corresponding author and can be reached via email at ywangssmu@shsmu.edu.cn.

    Conflicts of Interest

    None declared.

    Multimedia Appendix 1

    Complete electronic search strategies for PubMed, EMBASE, Cochrane CENTRAL, and Web of Science (1999-2025), showing Medical Subject Headings/Emtree terms, text words, and Boolean operators used to identify studies on diabetes and community-acquired pneumonia.

    DOCX File, 11 KB
    1. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. Jan 2022;183:109119. [CrossRef] [Medline]
    2. Cilloniz C, Torres A. Diabetes mellitus and pneumococcal pneumonia. Diagnostics (Basel). Apr 22, 2024;14(8):859. [CrossRef] [Medline]
    3. Ignatova GL, Blinova EV, Struch SV, Syrochkina MA. Risk of community acquired pneumonia in patients with diabetes mellitus: review. Ter Arkh. Mar 15, 2022;94(3):448-453. [CrossRef] [Medline]
    4. López-de-Andrés A, de Miguel-Díez J, Jiménez-Trujillo I, et al. Hospitalisation with community-acquired pneumonia among patients with type 2 diabetes: an observational population-based study in Spain from 2004 to 2013. BMJ Open. Jan 5, 2017;7(1):e013097. [CrossRef] [Medline]
    5. Darwitz BP, Genito CJ, Thurlow LR. Triple threat: how diabetes results in worsened bacterial infections. Infect Immun. Sep 10, 2024;92(9):e0050923. [CrossRef] [Medline]
    6. Silverii GA, Gabutti G, Tafuri S, et al. Diabetes as a risk factor for pneumococcal disease and severe related outcomes and efficacy/effectiveness of vaccination in diabetic population. Results from meta-analysis of observational studies. Acta Diabetol. Aug 2024;61(8):1029-1039. [CrossRef] [Medline]
    7. Torres A, Chalmers JD, Dela Cruz CS, et al. Challenges in severe community-acquired pneumonia: a point-of-view review. Intensive Care Med. Feb 2019;45(2):159-171. [CrossRef] [Medline]
    8. Kornum JB, Thomsen RW, Riis A, Lervang HH, Schønheyder HC, Sørensen HT. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care. Aug 2008;31(8):1541-1545. [CrossRef] [Medline]
    9. Balintescu A, Lind M, Franko MA, et al. Glycemic control and risk of sepsis and subsequent mortality in type 2 diabetes. Diabetes Care. Jan 1, 2022;45(1):127-133. [CrossRef] [Medline]
    10. Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. Nov 2019;157:107843. [CrossRef] [Medline]
    11. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. May 2020;8(5):475-481. [CrossRef] [Medline]
    12. Shang J, Yuan Z, Zhang Z, Zhou Q, Zou Y, Wang W. Effectiveness of continuous glucose monitoring on short-term, in-hospital mortality among frail and critically ill patients with COVID-19: randomized controlled trial. J Med Internet Res. Feb 7, 2025;27:e67012. [CrossRef] [Medline]
    13. Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 diabetes and its impact on the Immune system. Curr Diabetes Rev. May 12, 2020;16(5):442-449. [CrossRef]
    14. Grailer JJ, Canning BA, Kalbitz M, et al. Critical role for the NLRP3 inflammasome during acute lung injury. J Immunol. Jun 15, 2014;192(12):5974-5983. [CrossRef] [Medline]
    15. Han M, Ma K, Wang X, et al. Immunological characteristics in type 2 diabetes mellitus among COVID-19 patients. Front Endocrinol (Lausanne). 2021;12:596518. [CrossRef] [Medline]
    16. Carrillo-Larco RM, Anza-Ramírez C, Saal-Zapata G, et al. Type 2 diabetes mellitus and antibiotic-resistant infections: a systematic review and meta-analysis. J Epidemiol Community Health. Jan 2022;76(1):75-84. [CrossRef] [Medline]
    17. Knapp S. Diabetes and infection: is there a link?--A mini-review. Gerontology. 2013;59(2):99-104. [CrossRef] [Medline]
    18. Zhang X, Wu H, Fan B, et al. The role of age on the risk relationship between prediabetes and major morbidities and mortality: analysis of the Hong Kong diabetes surveillance database of 2 million Chinese adults. Lancet Reg Health West Pac. Jan 2023;30:100599. [CrossRef] [Medline]
    19. Costantini E, Carlin M, Porta M, Brizzi MF. Type 2 diabetes mellitus and sepsis: state of the art, certainties and missing evidence. Acta Diabetol. Sep 2021;58(9):1139-1151. [CrossRef] [Medline]
    20. Yang H, Yue R, Zhou J, et al. Study on metabonomics of Chinese herbal medicine in the treatment of type 2 diabetes mellitus complicated with community-acquired pneumonia. Medicine (Baltimore). 2020;99(37):e22160. [CrossRef]
    21. Yuan S, Chen Y, Xie L. Association between glucose levels at admission and outcomes of pneumonia: a systematic review and meta-analysis. BMC Pulm Med. Jul 30, 2024;24(1):369. [CrossRef] [Medline]
    22. Qambari H, Yu PK, Balaratnasingam C, Dickson J, Yu DY. Endothelial function can be modulated by acute hyperglycemia. Sci Rep. Aug 20, 2025;15(1):30559. [CrossRef] [Medline]
    23. Zeng W, Huang X, Luo W, Chen M. Association of admission blood glucose level and clinical outcomes in elderly community‐acquired pneumonia patients with or without diabetes. Clinical Respiratory J. Aug 2022;16(8):562-571. [CrossRef]
    24. Chen PC, Liao WI, Wang YC, et al. An elevated glycemic gap is associated with adverse outcomes in diabetic patients with community-acquired pneumonia. Medicine (Baltimore). Aug 2015;94(34):e1456. [CrossRef] [Medline]
    25. Banchini F, Vallisa D, Maniscalco P, Capelli P. Iron overload and Hepcidin overexpression could play a key role in COVID infection, and may explain vulnerability in elderly, diabetics, and obese patients. Acta Biomed. Sep 7, 2020;91(3):e2020013. [CrossRef] [Medline]
    26. Yang L, Han Y, Zhang T, et al. Human vascularized macrophage-islet organoids to model immune-mediated pancreatic β cell pyroptosis upon viral infection. Cell Stem Cell. Nov 7, 2024;31(11):1612-1629. [CrossRef] [Medline]
    27. Sartore G, Ragazzi E, Faccin L, Lapolla A. A role of glycation and methylation for SARS-CoV-2 infection in diabetes? Med Hypotheses. Nov 2020;144:110247. [CrossRef] [Medline]
    28. Gu L, Sun H, Yan Z. lncRNA ZEB1-AS1 is downregulated in diabetic lung and regulates lung cell apoptosis. Exp Ther Med. Dec 2020;20(6):225. [CrossRef] [Medline]
    29. Fliegerová KO, Mahayri TM, Sechovcová H, et al. Diabetes and gut microbiome. Front Microbiol. 2024;15:1451054. [CrossRef] [Medline]
    30. Yang J, Li J, Zhang L, et al. Highly diverse sputum microbiota correlates with the disease severity in patients with community-acquired pneumonia: a longitudinal cohort study. Respir Res. May 29, 2024;25(1):223. [CrossRef] [Medline]
    31. Zhou X, Shen X, Johnson JS, et al. Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease. Cell Host Microbe. Apr 10, 2024;32(4):506-526. [CrossRef] [Medline]
    32. Manzanares W, Lemieux M, Langlois PL, Wischmeyer PE. Probiotic and synbiotic therapy in critical illness: a systematic review and meta-analysis. Crit Care. Aug 19, 2016;19(1):262. [CrossRef] [Medline]
    33. Johnstone J, Meade M, Marshall J, et al. Probiotics: prevention of severe pneumonia and endotracheal colonization trial—PROSPECT: protocol for a feasibility randomized pilot trial. Pilot Feasibility Stud. Dec 2015;1(1):19. [CrossRef]
    34. Wikki I, Palmu J, Kauko A, et al. Prospective association between the gut microbiota and incident pneumonia: a cohort study of 6419 individuals. Respir Res. Dec 22, 2025;26(1):354. [CrossRef] [Medline]
    35. Millet Pascual-Leone B, Fiocca Vernengo F, Hillus D, et al. Community-acquired pneumonia in diabetic patients is characterised by a distinct pathogen spectrum and enhanced inflammation: results from CAPNETZ, a prospective observational cohort study. Infection. Oct 12, 2025. [CrossRef] [Medline]
    36. Aon M, Aoun AH, Al Shami A, et al. Association of diabetes mellitus with increased mortality in carbapenem-resistant enterobacterales infections. Cureus. Feb 2024;16(2):e53606. [CrossRef] [Medline]
    37. Pattolath A, Adhikari P, Pai V. Carbapenemase-producing Klebsiella pneumoniae infections in diabetic and nondiabetic hospitalized patients. Cureus. Jan 2024;16(1):e52468. [CrossRef] [Medline]
    38. Cunha BA, Burillo A, Bouza E. Legionnaires’ disease. Lancet. Jan 23, 2016;387(10016):376-385. [CrossRef] [Medline]
    39. Song JH, Thamlikitkul V, Hsueh PR. Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region. Int J Antimicrob Agents. Aug 2011;38(2):108-117. [CrossRef] [Medline]
    40. Zhu B, Wei X, Narasimhan H, et al. Inhibition of the mitochondrial pyruvate carrier simultaneously mitigates hyperinflammation and hyperglycemia in COVID-19. Sci Immunol. Apr 14, 2023;8(82):eadf0348. [CrossRef] [Medline]
    41. Kass-Gergi S, Zhao G, Wong J, et al. Disruption of immune responses by type 1 diabetes exacerbates SARS-CoV-2 mediated lung injury. Am J Physiol Lung Cell Mol Physiol. Dec 1, 2024;327(6):L839-L851. [CrossRef] [Medline]
    42. Garg A, Posa MK, Kumar A. Diabetes and deaths of COVID-19 patients: systematic review of meta-analyses. Health Sci Rev (Oxf). Jun 2023;7:100099. [CrossRef] [Medline]
    43. Klekotka RB, Mizgała E, Król W. The etiology of lower respiratory tract infections in people with diabetes. Pneumonol Alergol Pol. 2015;83(5):401-408. [CrossRef] [Medline]
    44. Lao M, Li C, Li J, Chen D, Ding M, Gong Y. Opportunistic invasive fungal disease in patients with type 2 diabetes mellitus from Southern China: clinical features and associated factors. J Diabetes Investig. May 2020;11(3):731-744. [CrossRef] [Medline]
    45. Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. Dec 2019;19(12):e405-e421. [CrossRef] [Medline]
    46. Weng NC, Yu WL. Isolation of Mycoplasma salivarium in the empyema of a diabetic patient with deep neck infection and necrotizing mediastinitis: a case report. IDCases. 2023;34:e01915. [CrossRef] [Medline]
    47. Holt RIG, Cockram CS, Ma RCW, Luk AOY. Diabetes and infection: review of the epidemiology, mechanisms and principles of treatment. Diabetologia. Jul 2024;67(7):1168-1180. [CrossRef] [Medline]
    48. Hashemi SH, Saki F, Borzouei S, Bawand R, Soltanian A. Comprehensive comparison of clinicoradiological, laboratory, and prognostic factors of community-acquired pneumonia in diabetic and nondiabetic hospitalized patients. Turk J Med Sci. 2023;53(6):1776-1785. [CrossRef] [Medline]
    49. Jensen AV, Baunbæk Egelund G, Bang Andersen S, et al. The glycemic gap and 90-day mortality in community-acquired pneumonia. A prospective cohort study. Ann Am Thorac Soc. Dec 2019;16(12):1518-1526. [CrossRef] [Medline]
    50. Vardakas KZ, Matthaiou DK, Falagas ME. Incidence, characteristics and outcomes of patients with severe community acquired-MRSA pneumonia. Eur Respir J. Nov 2009;34(5):1148-1158. [CrossRef] [Medline]
    51. Yao H, Zhou R, Wang J, et al. Pathogen‐targeting bimetallic nanozymes as ultrasonic‐augmented ROS generator against multidrug resistant bacterial infection. Adv Healthcare Mater. Oct 2023;12(25):2300449. [CrossRef]
    52. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. Oct 1, 2019;200(7):e45-e67. [CrossRef] [Medline]
    53. Martin-Loeches I, Torres A, Nagavci B, et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Eur Respir J. Apr 2023;61(4):2200735. [CrossRef] [Medline]
    54. Jeon MH, Chung JW, Choi SH, Kim TH, Lee EJ, Choo EJ. Pneumonia risk factors and clinical features of hospitalized patients older than 15 years with pandemic influenza A (H1N1) in South Korea: a multicenter study. Diagn Microbiol Infect Dis. Jun 2011;70(2):230-235. [CrossRef] [Medline]
    55. Amstutz A, Speich B, Mentré F, et al. Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. Lancet Respir Med. May 2023;11(5):453-464. [CrossRef] [Medline]
    56. Ning H, Chiu SH, Xu X, Ma Y, Chen JL, Yang G. The immunosuppressive roles of PD-L1 during influenza a virus infection. Int J Mol Sci. May 11, 2023;24(10):8586. [CrossRef] [Medline]
    57. Meagher RB, Lewis ZA, Ambati S, Lin X. Aiming for a bull’s-eye: targeting antifungals to fungi with dectin-decorated liposomes. PLoS Pathog. Jul 2021;17(7):e1009699. [CrossRef] [Medline]
    58. Barmanray RD, Cheuk N, Fourlanos S, Greenberg PB, Colman PG, Worth LJ. In-hospital hyperglycemia but not diabetes mellitus alone is associated with increased in-hospital mortality in community-acquired pneumonia (CAP): a systematic review and meta-analysis of observational studies prior to COVID-19. BMJ Open Diabetes Res Care. Jul 2022;10(4):e002880. [CrossRef] [Medline]
    59. American Diabetes Association Professional Practice Committee. 6. Glycemic goals and hypoglycemia: standards of care in diabetes—2025. Diabetes Care. Jan 1, 2025;48(1 Suppl 1):S128-S145. [CrossRef] [Medline]
    60. Shang J, Yuan Z, Zhang Z, Zhou Q, Zou Y, Wang W. Effectiveness of Continuous Glucose Monitoring on Short-Term, In-Hospital Mortality Among Frail and Critically Ill Patients With COVID-19: Randomized Controlled Trial. J Med Internet Res. Feb 7, 2025;27:e67012. [CrossRef] [Medline]
    61. Mohammed T, Bowe M, Plant A, Perez M, Alvarez CA, Mortensen EM. Metformin use is associated with lower mortality in veterans with diabetes hospitalized with pneumonia. Clin Infect Dis. Apr 3, 2023;76(7):1237-1244. [CrossRef] [Medline]
    62. Hong S, Wang H, Li S, Liu J, Qiao L. A systematic review and meta-analysis of glucocorticoids treatment in severe COVID-19: methylprednisolone versus dexamethasone. BMC Infect Dis. May 5, 2023;23(1):290. [CrossRef] [Medline]
    63. Badora-Musiał K, Sagan A, Domagała A, Kowalska-Bobko I. Testing the 2017 PHC reform through pilots: strengthening prevention and chronic care coordination. Health Policy. Feb 2021;125(2):185-190. [CrossRef] [Medline]
    64. Atun R, Davies JI, Gale EAM, et al. Diabetes in sub-Saharan Africa: from clinical care to health policy. Lancet Diabetes Endocrinol. Aug 2017;5(8):622-667. [CrossRef] [Medline]
    65. Ghit A. Pneumococcal vaccination in diabetic patients: review from clinical practice. Egypt J Intern Med. 2023;35(1):16. [CrossRef]
    66. Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax. Oct 2015;70(10):984-989. [CrossRef] [Medline]
    67. Bader MS, Yi Y, Abouchehade K, Haroon B, Bishop LD, Hawboldt J. Community-acquired pneumonia in patients with diabetes mellitus: predictors of complications and length of hospital stay. Am J Med Sci. Jul 2016;352(1):30-35. [CrossRef] [Medline]
    68. Pneumococcal vaccine recommendations. Centers for Disease Control and Prevention. URL: https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html [Accessed 2026-01-22]
    69. Dechates B, Porntharukchareon T, Sirisreetreerux S, et al. Immune response to CoronaVac and its safety in patients with type 2 diabetes compared with healthcare workers. Vaccines (Basel). Mar 17, 2023;11(3):684. [CrossRef] [Medline]
    70. Gassen NC, Papies J, Bajaj T, et al. SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals. Nat Commun. Jun 21, 2021;12(1):3818. [CrossRef] [Medline]
    71. Yen FS, Wei JCC, Shih YH, Hsu CC, Hwu CM. Metformin use and the risk of bacterial pneumonia in patients with type 2 diabetes. Sci Rep. Feb 28, 2022;12(1):3270. [CrossRef] [Medline]
    72. Desantis J, Mercorelli B, Celegato M, et al. Indomethacin-based PROTACs as pan-coronavirus antiviral agents. Eur J Med Chem. Dec 15, 2021;226:113814. [CrossRef] [Medline]
    73. Szymczak M, Pankowski JA, Kwiatek A, et al. An effective antibiofilm strategy based on bacteriophages armed with silver nanoparticles. Sci Rep. Apr 20, 2024;14(1):9088. [CrossRef] [Medline]
    74. Duan C, Xia WG, Zheng CJ, et al. Clinical observation on Jinhua Qinggan granule combined with conventional western medicine therapy in treating mild cases of coronavirus disease 2019 [Article in Chinese]. J Tradit Chin Med. 2020;61(17):1473-1477. [CrossRef]
    75. Yang XD, Yang YY. Ferroptosis as a novel therapeutic target for diabetes and its complications. Front Endocrinol. 2022;13. [CrossRef]
    76. Freedman BI, Wuerth JP, Cartwright K, et al. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials. Oct 1999;20(5):493-510. [CrossRef] [Medline]

    ‎
    ARDS: acute respiratory distress syndrome
    CAP: community-acquired pneumonia
    CGM: continuous glucose monitoring
    CRKP: carbapenem-resistant Klebsiella pneumoniae
    DM: diabetes mellitus
    GRADE: Grading of Recommendations Assessment, Development, and Evaluation
    HbA1c: glycosylated hemoglobin A1c
    ICU: intensive care unit
    IL: interleukin
    LMIC: low- and middle-income country
    MDR: multidrug-resistant
    NLRP3: NOD-like receptor thermal protein domain–associated protein 3
    OR: odds ratio
    RCT: randomized controlled trial

    Edited by Sheyu Li; submitted 11.Aug.2025; peer-reviewed by Akash Batta, Moses Ekwueme, Sunny Chi Lik Au; final revised version received 02.Jan.2026; accepted 02.Jan.2026; published 10.Mar.2026.

    Copyright

    © Yun Xie, Ao Zhang, Ying Wang, Ruilan Wang. Originally published in JMIR Diabetes (https://diabetes.jmir.org), 10.Mar.2026.

    This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Diabetes, is properly cited. The complete bibliographic information, a link to the original publication on https://diabetes.jmir.org/, as well as this copyright and license information must be included.